济川药业(600566) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 was ¥1,183,339,279.32, a decrease of 33.17% compared to the same period last year[5] - The total profit for the same period was ¥411,363,381.23, reflecting a decline of 38.22% year-over-year[5] - Net profit attributable to shareholders was ¥298,099,415.69, down 47.19% compared to the previous year[5] - The net profit after deducting non-recurring gains and losses was ¥238,626,673.03, a decrease of 54.00% year-over-year[5] - Basic earnings per share for Q3 2025 were ¥0.33, down 46.77% from the same period last year[6] - Total operating revenue for the first three quarters of 2025 was CNY 3,932,057,245.53, a decrease of 32.2% compared to CNY 5,805,134,511.20 in the same period of 2024[17] - Net profit for the first three quarters of 2025 was CNY 1,024,117,001.86, a decline of 46.3% compared to CNY 1,907,346,070.63 in 2024[18] - Earnings per share for the first three quarters of 2025 was CNY 1.11, down from CNY 2.07 in the same period of 2024[19] - The company reported a total profit of CNY 1,260,406,214.76 for the first three quarters of 2025, down 43.5% from CNY 2,233,497,637.20 in 2024[18] Cash Flow - The cash flow from operating activities for the year-to-date period decreased by 59.56%, totaling ¥703,511,369.40[5] - Cash flow from operating activities for the first three quarters of 2025 was CNY 703,511,369.40, a decrease of 59.6% compared to CNY 1,739,512,698.34 in 2024[20] - The net cash flow from investment activities was -$562.77 million, an improvement from -$2.08 billion in the previous period[21] - Total cash inflow from financing activities was $763.66 million, compared to $1.16 billion last year[21] - The net cash flow from financing activities decreased to -$1.68 billion from -$877.83 million year-over-year[21] - The ending balance of cash and cash equivalents was $5.13 billion, down from $6.52 billion in the previous year[21] - Cash received from investment activities totaled $4.46 billion, up from $2.75 billion year-over-year[21] - Cash paid for investments was $4.95 billion, compared to $4.68 billion in the previous period[21] - Cash paid for debt repayment was $495.02 million, down from $803.51 million last year[21] - Cash dividends and interest payments amounted to $1.92 billion, an increase from $1.21 billion in the previous year[21] - The cash inflow from investment income was $157.18 million, significantly higher than $31.80 million last year[21] - The cash outflow for financing activities totaled $2.44 billion, compared to $2.04 billion in the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥16,533,531,541.81, a decrease of 10.43% from the end of the previous year[6] - As of September 30, 2025, the total assets of the company amounted to RMB 16,533,531,541.81, a decrease from RMB 18,459,493,906.46 as of December 31, 2024, representing a decline of approximately 10.4%[14] - The company's current assets totaled RMB 12,945,450,807.22, down from RMB 14,702,020,835.04, indicating a decrease of about 12.0%[14] - The cash and cash equivalents decreased to RMB 5,129,898,303.50 from RMB 6,669,362,743.71, reflecting a decline of approximately 23.1%[14] - The company's total liabilities were RMB 2,675,766,914.17, down from RMB 3,733,067,567.74, showing a reduction of around 28.3%[15] - The total equity of the company was RMB 13,857,764,626.64, compared to RMB 14,726,426,338.72, indicating a decrease of about 5.9%[15] - The accounts receivable decreased to RMB 1,549,631,182.31 from RMB 2,173,363,209.42, representing a decline of approximately 28.7%[14] - The inventory decreased to RMB 344,742,726.96 from RMB 569,091,559.26, reflecting a reduction of about 39.4%[14] - The company's total non-current assets were RMB 3,588,080,734.59, down from RMB 3,757,473,071.42, representing a decrease of about 4.5%[14] - The company reported a significant reduction in accounts payable, which decreased to RMB 926,358,020.43 from RMB 1,438,254,024.28, indicating a decline of approximately 35.5%[15] Market Factors - The company attributed the decline in revenue primarily to changes in terminal market demand, particularly for products like Pudilan Oral Liquid and Children's Chiqiao Qingre Granules[9] - Research and development expenses for the first three quarters of 2025 were CNY 271,853,927.95, a decrease of 8.4% from CNY 296,861,461.95 in 2024[17] - Financial income for the first three quarters of 2025 was CNY 64,747,386.59, significantly lower than CNY 229,024,263.75 in the same period of 2024[18]